Lilly's Oral GLP-1 Outperforms Novo in ACHIEVE-3; US Obesity Decision in Q2 2026

MarketMoodz Analysis

For investors, the ACHIEVE-3 results shift the risk-reward balance toward Lilly’s oral GLP-1 franchise, potentially accelerating a shift in payer dynamics away from injectables if a compelling obesity indication lands in the U.S. in 2026. A successful early performance could also buoy Lilly’s valuation as a growth driver beyond metformin-era diabetes sales.

Historically, the GLP-1 space has been defined by injectable therapies, with Novo Nordisk’s Ozempic and Wegovy landmark products. The parallel development of oral GLP-1s creates a race to scale, with REDEFINE 4 presenting a contrasting data point for Novo’s CagriSema program—where non-inferiority against tirzepatide was not met after 84 weeks in an open-label design. The narrative now hinges on regulatory timing, safety signals, and commercial execution across 40+ countries.

What to watch next: await full trial data and regulatory submissions from Lilly, monitor FDA dialogue on a U.S. obesity indication in Q2 2026, and track payer coverage dynamics as oral GLP-1s seek share from injections; also watch Novo Nordisk’s response and any additional readouts from combined GLP-1 programs.